Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Eligible age
18+ yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment, after 1 year (52 weeks) of the treatment. The primary objective of this study are to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus switching to CAB and RPV in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.
Sponsor: Gilead Sciences
Where it's recruiting
Bakersfield · Beverly Hills · Hidden Valley Lake · Los Angeles …
New Haven
Washington D.C.
DeLand · Fort Lauderdale · Ft. Pierce · Miami Gardens …
Atlanta · Macon · Savannah
Burr Ridge · Chicago
Berkley
Kansas City
Sante Fe
The Bronx
Huntersville · Wilmington
Cincinnati
Source: ClinicalTrials.gov · NCT07682961 · last updated 2026-11-19